Corporate Banner
Satellite Banner
Technology Networks Header
Friday, August 22, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Aesica Introduces Aseptic Micro Dosing Capabilities at Nottingham Site
Tuesday, November 05, 2013
New technology (3P Fill2Weight) reduces development cycle and can be used with capsules, vials, inhalers, injectables, blisters and even high potents.

Aptiv Solutions ADDPLAN® DF is the First Validated Software to Use MCP-Mod Methodology
Thursday, October 31, 2013
MCP-Mod methodology was recently qualified by EMA for reducing bias and error in dose finding clinical trials.

Cobra Biologics Expands Antibody GMP Production Capacity
Tuesday, October 29, 2013
Company installs new 1000L HyClone SUB at the company’s centre of excellence.

Reducing Volume Losses During Fill and Finish
Thursday, October 24, 2013
Company will be presenting a poster at The Universe of Pre-Filled Syringes and Injection Devices PDA conference in Basel.

Cirrus - Kemwell Receives FDA Grant
Thursday, October 10, 2013
Grant to evaluate formulation effects on MDI performance.

Aesica Extends Aseptic Facilities at Nottingham Site
Tuesday, October 08, 2013
Batches can be delivered worldwide for clinical trials and within the EU for small-scale commercial production.

4SC Presents Summary of Biomarker and Patient Subgroup Analysis of Prognostic Factors
Tuesday, October 01, 2013
Further information about proposed role of biomarker ZFP64 in HCC tumour progression presented.

Almac Offering TruSight Tumor Profiling Next-Generation Sequencing Service
Monday, September 30, 2013
TruSight Tumor™ panel is specifically designed for use with FFPE samples.

Almac Launches SupplyTraQ™ Technology Solution
Tuesday, September 24, 2013
Online tool enables more cost-efficient and accurate reconciliation and reporting.

<< 2 3 4 5 6 7 8 >>
Showing Results 41 - 50 of 292
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv